CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Janus kinase (JAK) inhibitors, like baricitinib, are approved for alopecia areata (AA) but raise safety concerns due to broad immunosuppression.
• Developing selective JAK inhibitors is crucial for balancing therapeutic efficacy and drug safety in AA treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of CS12192, a selective JAK3 inhibitor, in an AA mouse model.
• To compare the therapeutic mechanisms of CS12192 with baricitinib using advanced molecular techniques.

Main Methods:

• Utilized a C3H/HeJ skin-transplanted alopecia areata mouse model.
• Employed mass cytometry (CyTOF) and RNA sequencing (RNA-seq) for in-depth mechanistic analysis.
• Assessed hair regrowth and immune cell infiltration in response to treatment.

Main Results:

• CS12192 demonstrated dose-dependent reversal of hair growth inhibition in AA mice.
• High-dose CS12192 showed efficacy comparable to baricitinib with enhanced safety.
• Both CS12192 and baricitinib significantly reduced immune cell infiltration, especially CD8+ T cells, in affected skin.

Conclusions:

• CS12192 is a potent selective JAK inhibitor with significant potential for treating alopecia areata.
• CS12192 exhibits a favorable safety profile compared to baricitinib, warranting further clinical investigation for AA.
• Mechanistic studies revealed shared pathways targeted by CS12192 and baricitinib in regulating AA immunopathology.